Guy A. Young, MD

Professor of Pediatrics (Clinical Scholar)

Image of Guy A. Young, MD
Is this your profile? Click to edit

Overview

Following medical school, I completed my residency in pediatrics at Schneider Children’s Hospital-Long Island Jewish Medical Center which is part of the Albert Einstein College of Medicine. I then completed a fellowship in pediatric hematology/oncology at Children’s National Medical Center in Washington, DC which is part of the George Washington University School of Medicine. I then began my research career at the Children’s Hospital of Orange County under the mentorship of Dr. Diane Nugent. There, I became interested in improving the treatment for patients with hemophilia and inhibitors and for children with blood clots. I received my first independent grants there inculding a grant from the FDA to study a new anticoagulant in children. In addition, I became interested in thromboelastography. In 2007, I moved the Children’s Hospital Los Angeles where I am continuing to perform research in the same areas as I had started in Orange County.

Awards

  • National Hemophilia Foundation: Physician of the Year, 2013

Research Funding

  • Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in children
    NIH · R01HL095110 · Sep 26, 2008 – Jan 31, 2013 · Role: Principal Investigator
  • FONDAPARINUM IN CHILDREN WITH THROMBOSIS
    NIH · R01FD003091 · Sep 20, 2006 – May 31, 2009 · Role: Principal Investigator

Publications

  • Emerging drugs for hemophilia A: insights into phase II and III clinical trials. Expert Opin Emerg Drugs. 2021 12; 26(4):337-350.. View in PubMed
  • The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia. 2021 Nov; 27(6):921-931.. View in PubMed
  • Post-hoc analysis on the long-term response to fixed-dose prophylaxis with N8-GP in patients with haemophilia A. Haemophilia. 2022 Jan; 28(1):27-35.. View in PubMed
  • Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays. Haemophilia. 2021 Sep; 27(5):730-735.. View in PubMed
  • Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making. Haemophilia. 2021 Sep; 27(5):724-729.. View in PubMed
  • Management of children with hemophilia A: How emicizumab has changed the landscape. J Thromb Haemost. 2021 07; 19(7):1629-1637.. View in PubMed
  • Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood. 2021 04 22; 137(16):2231-2242.. View in PubMed
  • Safety evaluation of emicizumab prophylaxis in individuals with haemophilia A. Expert Opin Drug Saf. 2021 Apr; 20(4):387-396.. View in PubMed
  • BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021 02 11; 137(6):763-774.. View in PubMed
  • Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. Haemophilia. 2021 Mar; 27(2):211-220.. View in PubMed